Dacetuzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDacetuzumab
Drug Alias Name达塞妥珠单抗S2C6 monoclonal antibodydacetuzumabum达西珠单抗hu-S2C6 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 inhibitors
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSeagen IncGenentech Inc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG